economic uncertainty as well as increasing health insurance premiums , deductibles and co-payments have resulted and may continue to result in cost-conscious consumers focusing on acute care rather than wellness , which has and may continue to adversely affect demand for our products and procedures . furthermore , governments and other third-party payors around the world facing tightening budgets could move to further reduce the reimbursement rates or the scope of coverage offered , which could adversely affect sales of our products . if the current adverse macroeconomic conditions continue , our business and prospects may be negatively impacted . in march 2010 , significant reforms to the healthcare system were adopted as law in the united states . the law includes provisions that , among other things , reduce and or limit medicare reimbursement , require all individuals to have health insurance ( with limited exceptions ) and imposes new and or increased taxes . specifically , the law requires the medical device industry to subsidize healthcare reform in the form of a 2.3 % excise tax on united states sales of certain medical devices effective january 1 , 2013. since the effective date of the medical device excise tax , the company has incurred $ 21.9 million and $ 15.7 million in fiscal 2014 and 2013 , respectively , of excise tax expense related to the domestic sales of its medical device products . the law also includes regulatory mandates and other measures designed to constrain medical costs , as well as stringent reporting requirements of financial relationships between medical device manufacturers and physicians and hospitals . compliance with the healthcare legislation , including these reporting requirements and the excise tax , has imposed significant additional administrative and financial burdens on us . various healthcare reform proposals have also emerged at the state level and in various foreign countries . the healthcare reform legislation and these proposals could reduce medical procedure volumes and impact the demand for our products or the prices at which we sell our products . in addition , the excise tax has increased our cost of doing business . these reforms , cost containment measures and new taxes , including the uncertainty in the medical community regarding their nature and effect , could also have an adverse effect on our customers ' purchasing decisions regarding our products and treatments and could harm our business , results of operations , financial condition and prospects . we operate in a highly regulated industry and other governmental actions may adversely affect our business , operations or financial condition , including , without limitation : new laws , regulations or judicial decisions , or new interpretations of existing laws , regulations or decisions , related to healthcare availability , methods of delivery and payment for healthcare products and services ; changes in the fda and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity ; changes in fda and foreign regulations that may require additional safety monitoring , labeling changes , restrictions on product distribution or use , or other measures after the introduction of our products to market , any of which could increase our costs of doing business , adversely affect the future permitted uses of approved products , or otherwise adversely affect the market for our products and treatments ; new laws , regulations and judicial decisions affecting pricing or marketing practices ; and changes in the tax laws relating to our operations , including those associated with the recently adopted healthcare reform law discussed above . professional societies , government agencies , practice management groups , private health/science foundations , and organizations involved in healthcare issues may publish guidelines , recommendations or studies to the healthcare and patient communities from time to time . recommendations of government agencies or these other groups/organizations may relate to such matters as usage , cost-effectiveness , and use of related preventative services and treatments/therapies . recommendations , guidelines or studies that are followed by patients and healthcare providers could result in decreased reimbursement or use of our products . for example , in november 2012 , the american congress of obstetrics and gynecologists , known as the acog , released updates in which they have recommended less frequent cervical cancer screening similar to guidelines released in march 2012 by the u.s. preventative services task force , known as the uspstf , and the american cancer society . however , the uspstf recommendations now also include hpv co-testing for certain patient populations , an update from their draft guidelines in october 2011. overall , we believe that these guidelines have contributed to an increase in testing intervals in the u.s. for cervical cancer screening , resulting in fewer such tests being performed . over the last few years , including in october 2014 , there have been periodic significant fluctuations in foreign currencies relative to the u.s. dollar . the ongoing fluctuations of the value of the u.s. dollar may cause our products to be less competitive in international markets and may impact sales and profitability over time . a majority of our international sales are denominated in foreign currencies . given the uncertainty in the worldwide financial markets , foreign currency fluctuations may be significant in the future and we may experience a material adverse effect on our international revenues and operating results . 41 acquisitions fiscal 2012 acquisition : gen-probe incorporated on august 1 , 2012 , we completed the acquisition of gen-probe for $ 3.97 billion , which was funded through available cash and financing consisting of senior secured credit facilities and senior notes resulting in aggregate proceeds of $ 3.48 billion , net of discounts . gen-probe 's revenue and pre-tax loss from continuing operations for the period from the acquisition date to september 29 , 2012 were $ 89.5 million and $ 47.7 million , respectively . story_separator_special_tag the measurement period for this contingent consideration ended in the second quarter of fiscal 2013 , and as such , there were no charges in fiscal 2014. impairment of goodwill . during the fourth quarter of fiscal 2013 , as a result of our company-wide annual budgeting and forecasting process and a full re-evaluation of our existing product development efforts and cost structure , we reduced our short term and long term revenue forecasts and determined that indicators of impairment existed in our molecular diagnostics reporting unit . the updated forecast , which reflected pricing pressures , for revenue and profitability was lower than those expected at the time of the gen-probe acquisition . as such , the fair value of this reporting unit declined . as a result of performing step 2 of the goodwill impairment test , which requires the completion of a hypothetical purchase price allocation to determine the fair value of the implied goodwill , we recorded a $ 1.1 billion goodwill impairment charge . for additional information , refer to note 2— “ intangible assets and goodwill ” to the consolidated financial statements contained in item 15 of this annual report . gain on sale of intellectual property . in the first quarter of fiscal 2013 , we recorded a net gain of $ 53.9 million related to the sale of our makena asset to k-v pharmaceutical company , or kv . on august 4 , 2012 , kv and certain of its subsidiaries filed voluntary petitions for reorganization under chapter 11 of title 11 of the united states code in the united states bankruptcy court for the southern district of new york . at that time , kv still owed us $ 95.0 million . in december 2012 , we executed a settlement agreement with kv and released kv from all claims in consideration of a $ 60.0 million payment . we recorded this payment , net of certain costs , in the first quarter of fiscal 2013. for additional information , please refer to note 7 contained in item 15 of this annual report . restructuring and divestiture charges . in the fourth quarter of fiscal 2012 , in connection with our acquisition of gen-probe , we implemented a restructuring action to consolidate our diagnostics operations by decreasing headcount and closing our legacy molecular diagnostics operations in madison , wisconsin . we also finalized our decision to transfer production of our interventional breast products from our indianapolis facility to our costa rica facility . in fiscal 2013 and in the first quarter of fiscal 2014 , we implemented cost containment measures that primarily resulted in headcount reductions . in the second , third and fourth quarters of fiscal 2014 , we terminated certain personnel at our hitec imaging operation in germany , and as part of ongoing management changes and structural refinement , we terminated certain executives and employees on a worldwide basis . pursuant to u.s. generally accepted accounting principles , the related severance and benefit charges are being recognized either ratably over the respective required employee service periods or when benefits become probable for contractual and statutory benefits , and other charges are being recognized as incurred . in fiscal 2014 and 2013 , we recorded aggregate charges of $ 51.7 million and $ 32.8 million , respectively , from these actions . the charges recorded in fiscal 2014 primarily related to severance and benefits and include a $ 3.1 million impairment charge to record certain buildings at our warstein , germany location to their estimated fair value . in addition , these charges include a loss on divestiture of $ 5.3 million related to the sale of our mri breast coils product line in the fourth quarter of fiscal 2014. the charges in fiscal 2013 primarily related to severance and benefits . in addition , in fiscal 2013 we recorded a net gain of $ 0.6 million primarily related to the sale 48 of our lifecodes business in the second quarter of fiscal 2013. for additional information , please refer to note 4 contained in item 15 of this annual report . interest income . years ended september 27 , 2014 september 28 , 2013 change amount amount amount % interest income $ 1.3 $ 1.3 $ — — % interest income remained flat in fiscal 2014 compared to fiscal 2013. interest expense . years ended september 27 , 2014 september 28 , 2013 change amount amount amount % interest expense $ ( 220.6 ) $ ( 281.1 ) $ 60.5 ( 21.5 ) % interest expense consists primarily of the cash interest costs and the related amortization of the debt discount and deferred financing costs on our outstanding debt . the decrease in interest expense in fiscal 2014 compared to fiscal 2013 was primarily due to principal payments in fiscal 2013 and 2014 , which included $ 325.0 million of voluntary pre-payments , of amounts borrowed under our credit agreement , lower weighted-average interest rates due to refinancing both the term loan a and term loan b facilities , and the redemption of $ 405.0 million in principal amount of our 2.00 % convertible notes due 2037 , or the 2007 notes , in december 2013. these decreases were partially offset by additional interest expense from the accretion of principal on our 2.00 % convertible notes due 2043 , or the 2013 notes , at 4.0 % annually . debt extinguishment loss . years ended september 27 , 2014 september 28 , 2013 change amount amount amount % debt extinguishment loss $ ( 7.4 ) $ ( 9.2 ) $ 1.8 ( 19.6 ) % in the second quarter of fiscal 2014 , we refinanced the term loan b facility of our credit agreement and voluntarily prepaid $ 25.0 million of principal . in connection with this transaction , we recorded a debt extinguishment loss of $ 4.5 million for the write off of the pro-rata share of the

liquidity and capital resources at september 27 , 2014 , we had $ 946.2 million of working capital , and our cash and cash equivalents totaled $ 736.1 million . our cash and cash equivalents balance decreased by $ 86.4 million during fiscal 2014 principally due to principal payments on our outstanding debt and capital expenditures partially offset by cash generated from operations and net proceeds from stock option exercises . in fiscal 2014 , our operating activities provided us with $ 508.4 million of cash , which included net income of $ 17.3 million , non-cash charges for depreciation and amortization aggregating $ 523.2 million , non-cash interest expense of $ 68.7 million related to our outstanding debt , stock-based compensation expense of $ 50.0 million , asset impairment charges of $ 38.4 million , and debt extinguishment losses of $ 7.4 million . these adjustments to net income were partially offset by a decrease in net deferred tax liabilities of $ 243.1 million , primarily from the amortization of intangible assets . cash provided by operations included a net cash inflow of $ 44.5 million from changes in our operating assets and liabilities . changes in our operating assets and liabilities were driven primarily by a decrease in prepaid income taxes of $ 22.4 million due to the timing of payments versus their utilization for our tax liability , a decrease in prepaid expenses and other assets of $ 17.3 million , an increase in deferred revenue of $ 15.1 million primarily due to an increase in our installed base of digital mammography systems , an increase in accrued expenses and other liabilities of $ 14.7 million primarily due to a net increase in bonus and benefits accruals , and restructuring and professional fees , partially offset by contingent consideration payments and lower accrued interest on our debt based on the timing of payments . these cash flow increases were partially offset by an increase in inventories of $ 44.7 million for expected demand and to build up our safety stock of instruments and assays primarily in our diagnostics business .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources at september 27 , 2014 , we had $ 946.2 million of working capital , and our cash and cash equivalents totaled $ 736.1 million . our cash and cash equivalents balance decreased by $ 86.4 million during fiscal 2014 principally due to principal payments on our outstanding debt and capital expenditures partially offset by cash generated from operations and net proceeds from stock option exercises . in fiscal 2014 , our operating activities provided us with $ 508.4 million of cash , which included net income of $ 17.3 million , non-cash charges for depreciation and amortization aggregating $ 523.2 million , non-cash interest expense of $ 68.7 million related to our outstanding debt , stock-based compensation expense of $ 50.0 million , asset impairment charges of $ 38.4 million , and debt extinguishment losses of $ 7.4 million . these adjustments to net income were partially offset by a decrease in net deferred tax liabilities of $ 243.1 million , primarily from the amortization of intangible assets . cash provided by operations included a net cash inflow of $ 44.5 million from changes in our operating assets and liabilities . changes in our operating assets and liabilities were driven primarily by a decrease in prepaid income taxes of $ 22.4 million due to the timing of payments versus their utilization for our tax liability , a decrease in prepaid expenses and other assets of $ 17.3 million , an increase in deferred revenue of $ 15.1 million primarily due to an increase in our installed base of digital mammography systems , an increase in accrued expenses and other liabilities of $ 14.7 million primarily due to a net increase in bonus and benefits accruals , and restructuring and professional fees , partially offset by contingent consideration payments and lower accrued interest on our debt based on the timing of payments . these cash flow increases were partially offset by an increase in inventories of $ 44.7 million for expected demand and to build up our safety stock of instruments and assays primarily in our diagnostics business .
```    
 Suspicious Activity Report : economic uncertainty as well as increasing health insurance premiums , deductibles and co-payments have resulted and may continue to result in cost-conscious consumers focusing on acute care rather than wellness , which has and may continue to adversely affect demand for our products and procedures . furthermore , governments and other third-party payors around the world facing tightening budgets could move to further reduce the reimbursement rates or the scope of coverage offered , which could adversely affect sales of our products . if the current adverse macroeconomic conditions continue , our business and prospects may be negatively impacted . in march 2010 , significant reforms to the healthcare system were adopted as law in the united states . the law includes provisions that , among other things , reduce and or limit medicare reimbursement , require all individuals to have health insurance ( with limited exceptions ) and imposes new and or increased taxes . specifically , the law requires the medical device industry to subsidize healthcare reform in the form of a 2.3 % excise tax on united states sales of certain medical devices effective january 1 , 2013. since the effective date of the medical device excise tax , the company has incurred $ 21.9 million and $ 15.7 million in fiscal 2014 and 2013 , respectively , of excise tax expense related to the domestic sales of its medical device products . the law also includes regulatory mandates and other measures designed to constrain medical costs , as well as stringent reporting requirements of financial relationships between medical device manufacturers and physicians and hospitals . compliance with the healthcare legislation , including these reporting requirements and the excise tax , has imposed significant additional administrative and financial burdens on us . various healthcare reform proposals have also emerged at the state level and in various foreign countries . the healthcare reform legislation and these proposals could reduce medical procedure volumes and impact the demand for our products or the prices at which we sell our products . in addition , the excise tax has increased our cost of doing business . these reforms , cost containment measures and new taxes , including the uncertainty in the medical community regarding their nature and effect , could also have an adverse effect on our customers ' purchasing decisions regarding our products and treatments and could harm our business , results of operations , financial condition and prospects . we operate in a highly regulated industry and other governmental actions may adversely affect our business , operations or financial condition , including , without limitation : new laws , regulations or judicial decisions , or new interpretations of existing laws , regulations or decisions , related to healthcare availability , methods of delivery and payment for healthcare products and services ; changes in the fda and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity ; changes in fda and foreign regulations that may require additional safety monitoring , labeling changes , restrictions on product distribution or use , or other measures after the introduction of our products to market , any of which could increase our costs of doing business , adversely affect the future permitted uses of approved products , or otherwise adversely affect the market for our products and treatments ; new laws , regulations and judicial decisions affecting pricing or marketing practices ; and changes in the tax laws relating to our operations , including those associated with the recently adopted healthcare reform law discussed above . professional societies , government agencies , practice management groups , private health/science foundations , and organizations involved in healthcare issues may publish guidelines , recommendations or studies to the healthcare and patient communities from time to time . recommendations of government agencies or these other groups/organizations may relate to such matters as usage , cost-effectiveness , and use of related preventative services and treatments/therapies . recommendations , guidelines or studies that are followed by patients and healthcare providers could result in decreased reimbursement or use of our products . for example , in november 2012 , the american congress of obstetrics and gynecologists , known as the acog , released updates in which they have recommended less frequent cervical cancer screening similar to guidelines released in march 2012 by the u.s. preventative services task force , known as the uspstf , and the american cancer society . however , the uspstf recommendations now also include hpv co-testing for certain patient populations , an update from their draft guidelines in october 2011. overall , we believe that these guidelines have contributed to an increase in testing intervals in the u.s. for cervical cancer screening , resulting in fewer such tests being performed . over the last few years , including in october 2014 , there have been periodic significant fluctuations in foreign currencies relative to the u.s. dollar . the ongoing fluctuations of the value of the u.s. dollar may cause our products to be less competitive in international markets and may impact sales and profitability over time . a majority of our international sales are denominated in foreign currencies . given the uncertainty in the worldwide financial markets , foreign currency fluctuations may be significant in the future and we may experience a material adverse effect on our international revenues and operating results . 41 acquisitions fiscal 2012 acquisition : gen-probe incorporated on august 1 , 2012 , we completed the acquisition of gen-probe for $ 3.97 billion , which was funded through available cash and financing consisting of senior secured credit facilities and senior notes resulting in aggregate proceeds of $ 3.48 billion , net of discounts . gen-probe 's revenue and pre-tax loss from continuing operations for the period from the acquisition date to september 29 , 2012 were $ 89.5 million and $ 47.7 million , respectively . story_separator_special_tag the measurement period for this contingent consideration ended in the second quarter of fiscal 2013 , and as such , there were no charges in fiscal 2014. impairment of goodwill . during the fourth quarter of fiscal 2013 , as a result of our company-wide annual budgeting and forecasting process and a full re-evaluation of our existing product development efforts and cost structure , we reduced our short term and long term revenue forecasts and determined that indicators of impairment existed in our molecular diagnostics reporting unit . the updated forecast , which reflected pricing pressures , for revenue and profitability was lower than those expected at the time of the gen-probe acquisition . as such , the fair value of this reporting unit declined . as a result of performing step 2 of the goodwill impairment test , which requires the completion of a hypothetical purchase price allocation to determine the fair value of the implied goodwill , we recorded a $ 1.1 billion goodwill impairment charge . for additional information , refer to note 2— “ intangible assets and goodwill ” to the consolidated financial statements contained in item 15 of this annual report . gain on sale of intellectual property . in the first quarter of fiscal 2013 , we recorded a net gain of $ 53.9 million related to the sale of our makena asset to k-v pharmaceutical company , or kv . on august 4 , 2012 , kv and certain of its subsidiaries filed voluntary petitions for reorganization under chapter 11 of title 11 of the united states code in the united states bankruptcy court for the southern district of new york . at that time , kv still owed us $ 95.0 million . in december 2012 , we executed a settlement agreement with kv and released kv from all claims in consideration of a $ 60.0 million payment . we recorded this payment , net of certain costs , in the first quarter of fiscal 2013. for additional information , please refer to note 7 contained in item 15 of this annual report . restructuring and divestiture charges . in the fourth quarter of fiscal 2012 , in connection with our acquisition of gen-probe , we implemented a restructuring action to consolidate our diagnostics operations by decreasing headcount and closing our legacy molecular diagnostics operations in madison , wisconsin . we also finalized our decision to transfer production of our interventional breast products from our indianapolis facility to our costa rica facility . in fiscal 2013 and in the first quarter of fiscal 2014 , we implemented cost containment measures that primarily resulted in headcount reductions . in the second , third and fourth quarters of fiscal 2014 , we terminated certain personnel at our hitec imaging operation in germany , and as part of ongoing management changes and structural refinement , we terminated certain executives and employees on a worldwide basis . pursuant to u.s. generally accepted accounting principles , the related severance and benefit charges are being recognized either ratably over the respective required employee service periods or when benefits become probable for contractual and statutory benefits , and other charges are being recognized as incurred . in fiscal 2014 and 2013 , we recorded aggregate charges of $ 51.7 million and $ 32.8 million , respectively , from these actions . the charges recorded in fiscal 2014 primarily related to severance and benefits and include a $ 3.1 million impairment charge to record certain buildings at our warstein , germany location to their estimated fair value . in addition , these charges include a loss on divestiture of $ 5.3 million related to the sale of our mri breast coils product line in the fourth quarter of fiscal 2014. the charges in fiscal 2013 primarily related to severance and benefits . in addition , in fiscal 2013 we recorded a net gain of $ 0.6 million primarily related to the sale 48 of our lifecodes business in the second quarter of fiscal 2013. for additional information , please refer to note 4 contained in item 15 of this annual report . interest income . years ended september 27 , 2014 september 28 , 2013 change amount amount amount % interest income $ 1.3 $ 1.3 $ — — % interest income remained flat in fiscal 2014 compared to fiscal 2013. interest expense . years ended september 27 , 2014 september 28 , 2013 change amount amount amount % interest expense $ ( 220.6 ) $ ( 281.1 ) $ 60.5 ( 21.5 ) % interest expense consists primarily of the cash interest costs and the related amortization of the debt discount and deferred financing costs on our outstanding debt . the decrease in interest expense in fiscal 2014 compared to fiscal 2013 was primarily due to principal payments in fiscal 2013 and 2014 , which included $ 325.0 million of voluntary pre-payments , of amounts borrowed under our credit agreement , lower weighted-average interest rates due to refinancing both the term loan a and term loan b facilities , and the redemption of $ 405.0 million in principal amount of our 2.00 % convertible notes due 2037 , or the 2007 notes , in december 2013. these decreases were partially offset by additional interest expense from the accretion of principal on our 2.00 % convertible notes due 2043 , or the 2013 notes , at 4.0 % annually . debt extinguishment loss . years ended september 27 , 2014 september 28 , 2013 change amount amount amount % debt extinguishment loss $ ( 7.4 ) $ ( 9.2 ) $ 1.8 ( 19.6 ) % in the second quarter of fiscal 2014 , we refinanced the term loan b facility of our credit agreement and voluntarily prepaid $ 25.0 million of principal . in connection with this transaction , we recorded a debt extinguishment loss of $ 4.5 million for the write off of the pro-rata share of the

